RENSSELAER, N.Y., July 31 (Bernama-GLOBE NEWSWIRE) — Taconic Biosciences, a global leader in providing drug discovery animal model solutions, announces the launch of the first commercially available diet-induced NASH (nonalcoholic steatohepatitis) rodent model.
NASH is a dangerous subtype of nonalcoholic fatty liver disease (NAFLD) and has recently garnered increased attention in the biomedical community due to its growing prevalence in the population. The National Institute of Diabetes and Digestive and Kidney Diseases estimates that between 30 and 40 percent of adults in the United States have NAFLD and about 3 to 12 percent of adults in the United States have NASH, which can lead to liver failure or liver cancer (https://www.niddk.nih.gov/health-information/liver-disease/nafld-nash/definition-facts).